We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




CRISPR Tool Enables Genome Repair by Precise RNA Editing

By LabMedica International staff writers
Posted on 06 Nov 2017
Print article
Image: A Cas13a molecule pictured with an RNA molecule (Photo courtesy of Lauren Solomon, Broad Communications).
Image: A Cas13a molecule pictured with an RNA molecule (Photo courtesy of Lauren Solomon, Broad Communications).
The CRISPR/Cas9 gene-editing tool has been modified to act as a promising RNA editing platform with broad applicability for research, therapeutics, and biotechnology.

CRISPR/Cas9 is regarded as the cutting edge of molecular biology technology. CRISPRs (clustered regularly interspaced short palindromic repeats) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacterial virus or plasmid. Since 2013, the CRISPR/Cas system has been used in research for gene editing (adding, disrupting, or changing the sequence of specific genes) and gene regulation. By delivering the Cas9 enzyme and appropriate guide RNAs into a cell, the organism's genome can be cut at any desired location. The conventional CRISPR/Cas9 system is composed of two parts: the Cas9 enzyme, which cleaves the DNA molecule and specific RNA guides that shepherd the Cas9 protein to the target gene on a DNA strand.

Investigators at the Broad Institute (Cambridge, MA, USA) and the Massachusetts Institute of Technology (Cambridge, USA) showed that a different CRISPR complex, CRISPR/Cas13a could be engineered for mammalian cell RNA knockdown and binding. To do this, the investigators engineered a Cas13 ortholog capable of robust knockdown and demonstrated RNA editing by using catalytically inactive Cas13 (dCas13) to direct adenosine to inosine deaminase activity via the enzyme ADAR2 to transcripts in mammalian cells.

Double-stranded RNA-specific adenosine deaminase is an enzyme that in humans is encoded by the ADAR (adenosine deaminase acting on RNA) gene. Adenosine deaminases acting on RNA (ADAR) are enzymes responsible for binding to double stranded RNA (dsRNA) and converting adenosine (A) to inosine (I) by deamination. As (I) is structurally similar to guanine (G), this induces (I) to (C) [cytosine] binding. The conversion from (A) to (I) disrupts the normal A:U pairing, which makes the RNA unstable. In both translation and replication (I) functions in a fashion similar to (G) in the RNA molecule.

Use of CRISPR\Cas13a enabled the investigators to develop a system, which they referred to as RNA Editing for Programmable A to I Replacement (REPAIR). This system, which had no strict sequence constraints, could be used to edit full-length transcripts containing pathogenic mutations. To demonstrate REPAIR's therapeutic potential, the investigators synthesized the pathogenic mutations that cause Fanconi anemia and X-linked nephrogenic diabetes insipidus, introduced them into human cells, and successfully corrected these mutations at the RNA level.

"The ability to correct disease-causing mutations is one of the primary goals of genome editing," said senior author Dr. Feng Zhang, professor of neuroscience at the Massachusetts Institute of Technology. "So far, we have gotten very good at inactivating genes, but actually recovering lost protein function is much more challenging. This new ability to edit RNA opens up more potential opportunities to recover that function and treat many diseases, in almost any kind of cell."

The CRISPR/Cas13-based REPAIR system was described in the October 25, 2017, online edition of the journal Science and the October 4, 2017, online edition of the journal Nature. The technology has been made freely available to researchers via the Zhang laboratory's page on the plasmid-sharing website Addgene.

Related Links:
Broad Institute
Massachusetts Institute of Technology
Addgene

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Troponin I Test
Quidel Triage Troponin I Test

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.